Instil Bio Announces Oral Presentation Of ITIL-306 Preclinical Data At British Society For Gene And Cell Therapy Annual Conference
Portfolio Pulse from Benzinga Newsdesk
Instil Bio announced the presentation of preclinical data for ITIL-306 at the British Society for Gene and Cell Therapy Annual Conference. The data showed enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors. ITIL-306 is expected to resume clinical study in 2H 2023, with initial clinical data anticipated in 2024.
June 26, 2023 | 8:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Instil Bio's presentation of ITIL-306 preclinical data showed enhanced activity of TILs against various tumors. Clinical study to resume in 2H 2023, with initial data expected in 2024.
The presentation of positive preclinical data for ITIL-306 indicates potential for the treatment's success in clinical trials. This could lead to increased interest and investment in Instil Bio, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100